# A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

Source: https://onco.cc/trials/nct07629726/  
OnCo record `nct07629726` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of KK2430 in advanced solid tumours, run by Kyowa Kirin Co., Ltd., now recruiting.

## Summary

A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms is a phase 1/2 interventional study registered as NCT07629726 by Kyowa Kirin Co., Ltd., with 72 participants planned, started 2026-08 and due to reach its primary completion in 2027-04. Interventions recorded: KK2430.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07629726
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms
- Sponsor: Kyowa Kirin Co., Ltd.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT07629726: https://clinicaltrials.gov/study/NCT07629726

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Kyowa Kirin](https://onco.cc/companies/kyowa-kirin/)

---
JSON: https://onco.cc/api/v1/entities/nct07629726.json